The annual LUGPA meeting in November 2023 wasn’t just about the latest in urological pathology – it was the stage for a groundbreaking innovation that promises to transform prostate biopsy workflow: the patent-pending TWOD (Tissue Workflow Optimization Digital) system, a joint venture between GoPath and its subsidiary, DigitCells.

Designed by the visionary company, DigitCells, TWOD tackles a major pain point in prostate biopsy – specimen loss and inefficient processing. Traditionally, biopsies placed in formalin jars can get lost, broken, or stuck to the edges, creating delays and errors.

TWOD introduces a paradigm shift: a proprietary cassette system with designated areas for each core biopsy. This not only prevents loss but also allows for standardized placement, enabling:

• Easier tracking: Barcodes and digital logging follow the specimen from the clinician’s hands through the lab and into the IMS (Laboratory Information System).
• Consolidated slides: Multiple cores can be placed on a single slide, providing a comprehensive overview in a single digital image.

• Automated analysis: This digitized format paves the way for AI-powered tools to analyze tissue cores, offering automated tumor involvement and Gleason scoring.

But TWOD’s innovation goes beyond mere tracking. The system also features:

• Automatic gross imaging: Each core is automatically photographed, capturing measurements and logging gross appearances for future reference in the LIS.

• Streamlined workflow: TWOD integrates seamlessly with existing lab processes, minimizing manual steps and delays.

The benefits for pathologists, clinicians, and ultimately patients are numerous:

• Reduced errors: Accurate tracking and standardized processing minimize the risk of misdiagnosis and delays.

• Improved efficiency: Streamlined workflow saves time and resources, allowing labs to handle more cases efficiently.

• Enhanced diagnostics: AI-powered analysis provides faster, more accurate diagnoses, potentially leading to better patient outcomes.

TWOD’s debut at LUGPA 2023 generated significant excitement within the urological pathology community. This innovative system, born from the collaboration of GoPath and DigitCells, has the potential to revolutionize prostate biopsy workflow, ultimately leading to improved patient care and outcomes.

Want to learn more about TWOD and its transformative potential? Visit the DigitCells websites or contact them at [email protected] for further information. Be a part of the future of prostate biopsy – embrace the TWOD revolution!

Author

Scott Kilcoyne
DigitCells Cofounder & COO